These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31188048)

  • 1. The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
    Rassy E; Bakouny Z; Assi T; Karak FE; Pavlidis N
    Immunotherapy; 2019 Jul; 11(10):913-920. PubMed ID: 31188048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
    Papachristofilou A; Hipp MM; Klinkhardt U; Früh M; Sebastian M; Weiss C; Pless M; Cathomas R; Hilbe W; Pall G; Wehler T; Alt J; Bischoff H; Geißler M; Griesinger F; Kallen KJ; Fotin-Mleczek M; Schröder A; Scheel B; Muth A; Seibel T; Stosnach C; Doener F; Hong HS; Koch SD; Gnad-Vogt U; Zippelius A
    J Immunother Cancer; 2019 Feb; 7(1):38. PubMed ID: 30736848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.
    Bleehen NM; Ball D; Belani CP; Bishop J; Douillard JY; Cox JD; Johnson DH; Le Chevalier T; Saunders MI; Shaw E
    Lung Cancer; 1994 Mar; 10 Suppl 1():S19-23. PubMed ID: 8087510
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
    Reck M
    Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
    Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
    Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
    J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.